Clinical trial · Observational
Added Value of Gadoxetic Acid-enhanced Liver MRI
Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It would be valuable to evaluate whether gadoxetic acid-enhanced liver MRI would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at CT and to reduce the necessity of biopsy in patients with high risk of HCC. Therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced MRI for diagnosis of HCC in patients with small (10-19mm) or atypical hepatic nodules at CT.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnosis | — | UNRESOLVED | — |
| Hcc | Hepatocellular Carcinoma | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gadoxetic acid-enhanced liver MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients group
- description
- * with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or \> 20mm) and high-risk group of HCC * scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy
- interventionNames
- Procedure: gadoxetic acid-enhanced liver MRI
- label
- Living liver donor candidates
- description
- * living liver donor candidates without history of liver disease * schedule for gadoxetic acid-enhanced liver MRI as preoperative workup * only used for control of normal liver parenchymal enhancement on hepatobiliary phase
- interventionNames
- Procedure: gadoxetic acid-enhanced liver MRI
Primary outcomes (1)
- measure
- sensitivity to diagnose HCC, per-nodule base
- timeFrame
- 12 months after MRI
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with chronic hepatitis B or cirrhosis of any etiology * signed informed consent AND * being referred to radiology department for gadoxetic acid-enhanced MRI due to small nodule (10-19mm) at contrast-enhanced CT scan within 30 days as an radiofrequency ablation (RFA) work-up OR * being referred to radiology department for percutaneous biopsy for atypical hepatic nodules (≥20mm) detected at contrast-enhanced CT within 30 days before biopsy Exclusion Criteria: * Any contraindication for MRI and MR contrast agent
References
Publications (0)
Data not yet available